NRG-BN010 immuno-RT combination failed to improve response in recurrent glioblastoma
Tocilizumab, atezolizumab and 24 Gy/3-fraction FSRT produced only a 3.4% objective response rate in recurrent glioblastoma.
Tag
immuno-rt
Living ESTRO/OligoCare review maps safety signals for SRT with modern systemic therapy
Across 7,694 patients, most SRT–systemic therapy combinations appeared tolerable, but BRAF/MEK inhibitors, T-DM1 and liver SRT showed caution signals.
Chemotherapy-free RT plus durvalumab was feasible in PD-L1-high locally advanced NSCLC
Concurrent durvalumab with either 60 Gy/15 or 60 Gy/30 was feasible in a 24-patient phase I study without concurrent chemotherapy.
ICI timing did not change pathological response when neoadjuvant ESCC backbones were matched
Concurrent and consolidation ICI produced similar pathological response rates once analyses were restricted to neoadjuvant chemoradiotherapy studies.
Metformin reshaped glioblastoma immunity and improved radiotherapy response in mice
Metformin plus radiotherapy prolonged survival in two syngeneic glioblastoma models while shifting macrophage and T-cell populations toward antitumor phenotypes.
SBRT plus dual checkpoint blockade produced 72.7% six-month PFS in oligometastatic HNSCC
Durvalumab, tremelimumab and SBRT produced 72.7% six-month progression-free survival in 33 patients with oligometastatic HNSCC.
Short-course radiotherapy may be a stronger immunotherapy partner in rectal cancer
Recent trials report 40–61% pathologic complete response with short-course radiotherapy plus immunotherapy, but mature comparative outcomes remain unavailable.
Experts prioritized biomarker-guided radiotherapy–systemic therapy trials in head and neck cancer
International experts identified eight research priorities covering biomarker-guided chemoradiation, immunotherapy sequencing, and consolidation radiotherapy in metastatic head and neck cancer.
Stereotactic radiotherapy plus atezolizumab missed the AZTEC efficacy target
Neither fractionation schedule rejected the prespecified progression-free survival benchmark; durable benefit was confined to patients with oligometastatic disease.
Anal cancer radiotherapy–immunotherapy trials remain too heterogeneous for direct comparison
Twelve trials used 14 immunotherapy regimens with major differences in eligibility, radiotherapy, chemotherapy, endpoints, and translational analysis.
Concurrent atezolizumab was linked to HSV-1 toxicity during adaptive head and neck radiotherapy
Radiation reached 60 Gy in 15 fractions with adjuvant atezolizumab, while concurrent dosing was followed by HSV-1 reactivation in three of five patients.
Durvalumab with radiotherapy achieved 39% two-year PFS in cCRT-ineligible NSCLC
Concurrent and consolidative durvalumab with definitive radiotherapy produced 39% two-year progression-free survival in patients ineligible for concurrent chemoradiotherapy.
Intratumoral polyvinyl chloride was associated with radioresistance in hepatocellular carcinoma
PVC was detected in 37 of 72 HCC tumors and was associated with poorer response and progression-free survival after SBRT, immunotherapy, and bevacizumab.
Durvalumab improved 2-year progression-free survival after chemoradiotherapy in real-world stage III NSCLC
Consolidation durvalumab after concurrent chemoradiotherapy halved the adjusted risk of progression or death at two years in real-world stage III NSCLC.
Timing shaped radiotherapy-immunotherapy synergy across mechanisms
This systematic review found that optimal radiotherapy-immunotherapy sequencing depends on the immune mechanism being targeted.